Latest News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.

Sovaldi Rx are being filled, despite payer angst

Sovaldi Rx are being filled, despite payer angst

Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.

Web Exclusives

Data security in pharma marketing—the path to maturity

Data security in pharma marketing—the path to maturity

What brand managers need to know to achieve data security maturity

Blockbuster Drug Boycott? What ESI's Sovaldi Threat Means to Big Pharma

Blockbuster Drug Boycott? What ESI's Sovaldi Threat Means to Big Pharma

Express Scripts warned of building an anti-Sovaldi coalition. If payers are unwilling to pay for such drugs, or band against their makers, where does pharma go from here?

In Brief

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.

MM&M Awards Gallery

A Star-Studded Evening

Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner

MM&M EBOOKS

The new MM&M e-book, "Oncology Marketing," is designed to serve as a companion for those in the business of communicating cancer products to all three stakeholders. It's packed with analysis, advice, insights and commentary to help navigate the terrain. Click here to access it.

MM&M inVision

Agency Spotlight


Email Newsletters